Abstract
Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Recent Patents on Anti-Cancer Drug Discovery
Title:Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Volume: 8 Issue: 2
Author(s): Riccardo Petrelli, Patrizia Vita, Ilaria Torquati, Krzysztof Felczak, Daniel J. Wilson, Palmarisa Franchetti and Loredana Cappellacci
Affiliation:
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Abstract: Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Export Options
About this article
Cite this article as:
Petrelli Riccardo, Vita Patrizia, Torquati Ilaria, Felczak Krzysztof, J. Wilson Daniel, Franchetti Palmarisa and Cappellacci Loredana, Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020001
DOI https://dx.doi.org/10.2174/1574892811308020001 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry <i>Anastatica hierochuntica </i>Extracts: Promising, Safe and Selective Anticancer Agents
The Natural Products Journal The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Current Cancer Drug Targets Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Discovery and Design of Peptides as MMP9 Inhibitors through Structure-Based Molecular Docking for Targeted Mantle Cell Lymphoma Therapy
Anti-Cancer Agents in Medicinal Chemistry 9-Hydroxyellipticine and Derivatives as Chemotherapy Agents
Mini-Reviews in Medicinal Chemistry Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Autophagy Driven Extracellular Vesicles in the Leukaemic Microenvironment
Current Cancer Drug Targets MicroRNAs - Key Players in Haematopoiesis
Current Signal Transduction Therapy Metabolic Effects of Resveratrol in Mammals - a Link Between Improved Insulin Action and Aging
Current Aging Science